Imidazo[1,2-a]pyridines as cholesterol 24-hydroxylase (CYP46A1) inhibitors: a patent evaluation (WO2014061676) [0.03%]
作为胆固醇24-羟基酶(CYP46A1)抑制剂的咪唑并[1,2-a]吡啶类专利点评(WO2014061676)
Yoshikazu Uto
Yoshikazu Uto
A series of imidazo[1,2-a]pyridine analogs that effectively inhibit cholesterol 24-hydroxylase (CYP46A1) was reported in WO2014061676. The treatment or prophylaxis of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's ...
A Key Opinion Leader interview: insight into the research and career of Dr KA Jacobson [0.03%]
一个关键意见领袖的访谈：对KA雅各布森博士的研究和职业生涯的见解
Kenneth A Jacobson,Claudia Palmer
Kenneth A Jacobson
Roberto Costante,Azzurra Stefanucci,Simone Carradori et al.
Roberto Costante et al.
Introduction: Dipeptidyl peptidase 4 (DPP-4) is a serine protease, which catalyzes the hydrolytic process of the amide bond X-Ala or X-Pro at the N-terminus of peptides. This enzyme is involved in the degradation of two i...
Taichi Ohshiro,Hiroshi Tomoda
Taichi Ohshiro
Introduction: Acyltransferase (AT) catalyzes the transfer of an acyl moiety from acyl-coenzyme A (acyl-CoA) to an acceptor. ATs play important roles in the maintenance of homeostasis in the human body and have been linked...
The use of iron chelators in biocidal compositions: evaluation of patent, WO2014059417A1 [0.03%]
铁螯合剂在杀生物组合物中的应用：对专利WO2014059417A1的评估
Sumit Sahni,Sukriti Krishan,Duraippandi Palanimuthu et al.
Sumit Sahni et al.
Anti-microbial-potentiating compositions, containing one or more anti-microbial agents and an iron chelator, are claimed in the patent application. Different combinations of anti-microbial agents with various classes of iron chelators are c...
KDM4 histone demethylase inhibitors for anti-cancer agents: a patent review [0.03%]
抗癌剂组蛋白去甲基酶KDM4抑制剂的专利点评
Young-Won Chin,Sun-Young Han
Young-Won Chin
Introduction: As epigenetic modulators, histone demethylases can be a therapeutic target in the area of oncology. KDM4 subfamily proteins are histone demethylases with a Jumonji domain. The subfamily consists of five func...
Novel metabotropic glutamate receptor 2/3 antagonists and their therapeutic applications: a patent review (2005 - present) [0.03%]
新型代谢型谷氨酸受体2/3拮抗剂及其治疗应用专利回顾(2005-至今)
Sylvain Celanire,Iyassu Sebhat,Juergen Wichmann et al.
Sylvain Celanire et al.
Introduction: This review focuses on the medicinal chemistry efforts directed toward the identification of competitive and noncompetitive antagonists of glutamate at group II metabotropic glutamate receptors (mGluRII: mGl...
Paolo Mellini,Sergio Valente,Antonello Mai
Paolo Mellini
Introduction: Since 2000 sirtuins (SIRT1-7) have gained growing attention for their connections with many biological processes such as cellular metabolism regulation, neuroprotection, apoptosis, inflammation, and cancer p...
Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014) [0.03%]
针对HIV-1gp41的肽融合抑制剂专利回顾（2009-2014）
Dongmei Zhang,Wen Li,Shibo Jiang
Dongmei Zhang
Introduction: As the first peptide HIV fusion inhibitor targeting gp41, enfuvirtide (T20) was approved by the US FDA in 2003 as a salvage therapy for HIV/AIDS patients who failed to respond to the then existing antiretrov...
PPARγ ligands and their therapeutic applications: a patent review (2008 - 2014) [0.03%]
PPARγ配体及其治疗应用（2008-2014）专利回顾
Ichiro Takada,Makoto Makishima
Ichiro Takada
Introduction: PPARγ regulates glucose and lipid metabolism, immunity, and cellular growth and differentiation. Thiazolidinediones (TZDs) are synthetic PPARγ ligands that are used in the treatment of type 2 diabetes. How...